A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Description

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Conditions

Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Santa Ana

Southern California Clinical Research, Santa Ana, California, United States, 92701

Aurora

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Hamden

CMR of Greater New Haven, LLC, Hamden, Connecticut, United States, 06517

Cooper City

ALL Medical Research, LLC, Cooper City, Florida, United States, 33024

Coral Gables

Florida International Medical Research, Coral Gables, Florida, United States, 33134

Ocala

Renstar Medical Research, Ocala, Florida, United States, 34470

Orlando

Charter Research - Winter Park, Orlando, Florida, United States, 32803

West Palm Beach

Metabolic Research Institute, Inc., West Palm Beach, Florida, United States, 33401

Marietta

Kubost Clinical Research - Marietta, Marietta, Georgia, United States, 30062

Woodstock

North Georgia Clinical Research, Woodstock, Georgia, United States, 30189

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight
  • * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
  • * Have a prior or planned surgical treatment for obesity
  • * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity
  • * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
  • * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • * Have had within the past 90 days before screening:
  • * acute myocardial infarction
  • * cerebrovascular accident (stroke)
  • * hospitalization for unstable angina, or
  • * hospitalization due to congestive heart failure
  • * Have New York Heart Association Functional Classification Class IV congestive heart failure
  • * Have a history of chronic or acute pancreatitis
  • * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2028-04